与抑郁症相关的血栓形成风险的分子调节机制
Rong Wang1, Fan Xiao2, Weiwei Peng1
1Hunan Vocational College of Electronic and Technology, School of Medicine and Pharmacy, Changsha, Hunan, China.
Journal of medical biochemistry
|March 9, 2026
概括
抑郁症显著增加了由于炎症和血小板过活性的血栓形成风险,独立于抑郁症的严重程度. 这凸显了对高风险个体进行综合精神病学查和潜在针对性干预的需要.
科学领域:
- 心血管医学 心血管医学
- 精神病学是一个精神病学.
- 血液学 血液学 血液学
背景情况:
- 抑郁症影响全球超过2.8亿人,增加了血栓事件的风险 (例如,DVT,PE).
- 抑郁症,炎症,血小板激活和凝血之间的病理生理联系仍然不清楚.
- 有必要进行研究,以了解这些关联,并探索抑郁症中血栓性并发症的护理干预措施.
研究的目的:
- 确定连接血栓和抑郁症的生物途径.
- 检查炎症和凝血生物标志物作为血栓形成风险的独立预测因素.
- 研究护理干预措施的潜力,以减少抑郁症患者的血栓性并发症.
主要方法:
- 500名参与者参加的病例控制研究 (250名患有重度抑郁症,250名对照).
- 使用ELISA和qPCR进行量化炎症 (IL-6,TNF-a,CRP) 和凝血 (D-二聚合物,纤维原) 生物标志物.
- 通过流细胞测量评估了血小板激活;进行了12个月的随访和多变量回归分析.
主要成果:
- 抑郁症患者的血栓和炎症标志物显著增加 (p<0.001).
- 观察到高调的血小板激活标志物的高凝血状态.
- 抑郁症 (OR=2.10),IL-6 (OR=1.92) 和血小板激活 (OR=2.50) 独立预测了血栓形成的风险.
结论:
- 抑郁症是血栓形成的独立风险因素,由系统性炎症和血小板过活力介导.
- 结果支持将精神病学查纳入血栓形成风险评估.
- 表明抗炎症或抗血小板疗法对高风险精神病患者群体的潜在益处.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Depressive Disorders: Etiology
819
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
819
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
80
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
80
Depression: Overview
1.1K
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
1.1K
Disorders of Hemostasis
2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K


